Search Within

David Hyman

  1. "2019"
Formats
  1. Meeting Abstract (44)
  2. Journal Article (24)
  3. Research Letter (3)
  4. Review (2)
  5. Editorial (1)
Groups
  1. Department of Medicine (74)
  2. Early Drug Development Service (74)
  3. Solid Tumor Oncology Division (74)
  4. GSK Faculty (39)
  5. Hematology-Oncology Fellows (36)
  6. Human Oncology and Pathogenesis Program (34)

More Groups

People
  1. Alexander Drilon (24)
  2. Marc Ladanyi (23)
  3. Michael Berger (21)
  4. David Solit (19)
  5. Ahmet Zehir (16)
  6. Alison Schram (14)

More People

Years
  1. 2019 (74)
Publications
  1. Cancer Research (15)
  2. Annals of Oncology (13)
  3. Journal of Clinical Oncology (9)
  4. JCO Precision Oncology (7)
  5. Clinical Cancer Research (6)
  6. Nature Medicine (4)

More Publications

Publishers
  1. American Association for Cancer Research (24)
  2. American Society of Clinical Oncology (16)
  3. Oxford University Press (14)
  4. Nature Publishing Group (8)
  5. Elsevier Inc. (3)
  6. Elsevier Science, Inc. (3)

More Publishers

Results (74)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Extended mutational profiling by MSK-IMPACT™ identifies mutations predicting thromboembolic risk in patients with solid tumor malignancy
    Meeting Abstract

    Dunbar, A.; Bolton, K.; Devlin, S. M.; Sanchez-Vega, F.; Gao, J.; Mones, J. V.; Wills, J. M.; Kelly, D.; Farina, M.; Kishore, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without FGFR alterations
    Journal Article

    Hyman, D. M.; Tran, B.; Paz-Ares, L.; Machiels, J. P.; Schellens, J. H.; Bedard, P. L.; Campone, M.; Cassier, P. A.; Sarantopoulos, J.; Vaishampayan, U.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors
    Meeting Abstract

    Tolcher, A.; Hafez, N.; Yamamoto, N.; Park, J.; Grempler, R.; Lucarelli, A.; Vallaster, M. P.; Wang, B. S.; Hyman, D.
    Molecular Cancer Therapeutics (2019)

    Fulltext@MSK | Save
  • Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
    Meeting Abstract

    Schram, A. M.; O'Reilly, E. M.; Somwar, R.; Benayed, R.; Shameem, S.; Chauhan, T.; Torrisi, J.; Ford, J.; Maussang, D.; Wasserman, E.; more...
    Molecular Cancer Therapeutics (2019)

    Fulltext@MSK | Save
  • Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumors
    Meeting Abstract

    Doz, F.; Geoerger, B.; DuBois, S. G.; Grilley-Olson, J. E.; van Tilburg, C. M.; Italiano, A.; Lissat, A.; Kang, H. J.; Tahara, M.; Boni, V.; more...
    Neuro-Oncology (2019)

    Fulltext@MSK | Save
  • Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
    Meeting Abstract

    Ziegler, D. S.; Doz, F.; Geoerger, B.; Dubois, S.; Grilley-Olson, J. E.; van Tilburg, C.; Italiano, A.; Lissat, A.; Kang, J. H.; Tahara, M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
    Meeting Abstract

    Hyman, D.; Tan, D. S. W.; van Tilburg, C.; Albert, C.; Geoerger, B.; Farago, A.; Laetsch, T.; Kummar, S.; Doz, F.; Lassen, U.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy of vemurafenib in patients with non–small-cell lung cancer with BRAF V600 mutation: An open-label, single-arm cohort of the histology-independent VE-Basket study
    Journal Article

    Subbiah, V.; Gervais, R.; Riely, G.; Hollebecque, A.; Blay, J. Y.; Felip, E.; Schuler, M.; Gonçalves, A.; Italiano, A.; Keedy, V.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases
    Journal Article

    Guo, R.; Schreyer, M.; Chang, J. C.; Rothenberg, S. M.; Henry, D.; Cotzia, P.; Kris, M. G.; Rekhtman, N.; Young, R. J.; Hyman, D. M.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer
    Journal Article

    Cadoo, K. A.; Mandelker, D. L.; Mukherjee, S.; Stewart, C.; DeLair, D.; Ravichandran, V.; Srinivasan, P.; Hurley, D.; Kemel, Y.; Arnold, A. G.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save